Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pilot study of blood biomarker candidates for detection of pancreatic cancer.

Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP, Brentnall TA.

Pancreas. 2010 Oct;39(7):981-8. doi: 10.1097/MPA.0b013e3181dac920.

2.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

3.

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.

Clin Cancer Res. 2006 Jan 15;12(2):442-6.

4.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.

PMID:
19789838
5.

Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.

Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, Milless BP, Goodlett DR, Rush J, Brentnall TA.

J Proteome Res. 2012 Mar 2;11(3):1937-48. doi: 10.1021/pr201117w. Epub 2012 Feb 8.

6.

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.

Pancreas. 2013 Mar;42(2):193-7. doi: 10.1097/MPA.0b013e31825e354d.

7.

CEACAM1, a novel serum biomarker for pancreatic cancer.

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.

Pancreas. 2007 May;34(4):436-43.

PMID:
17446843
8.

Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.

Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ.

World J Surg. 2009 Apr;33(4):716-22. doi: 10.1007/s00268-008-9853-9.

9.

Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.

Ward DG, Wei W, Buckels J, Taha AM, Hegab B, Tariciotti L, Salih R, Qi YQ, Martin A, Johnson PJ.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1358-63. doi: 10.1097/MEG.0b013e32833b6d41.

PMID:
20555269
10.

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.

Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A, Lokshin AE.

PLoS One. 2014 Apr 18;9(4):e94928. doi: 10.1371/journal.pone.0094928. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117876. Huang, Ying [added].

11.

Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.

Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, Hauss J, Büchler M, Thiery J.

Clin Cancer Res. 2009 Jun 1;15(11):3812-9. doi: 10.1158/1078-0432.CCR-08-2701. Epub 2009 May 26.

12.

Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.

Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, Song SY, Kim H, Hancock WS, Paik YK.

J Proteome Res. 2014 Nov 7;13(11):4878-88. doi: 10.1021/pr5002719. Epub 2014 Aug 8.

PMID:
25057901
13.

A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Balasenthil S, Chen N, Lott ST, Chen J, Carter J, Grizzle WE, Frazier ML, Sen S, Killary AM.

Cancer Prev Res (Phila). 2011 Jan;4(1):137-49. doi: 10.1158/1940-6207.CAPR-10-0025. Epub 2010 Nov 11.

14.

Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA.

J Proteome Res. 2011 May 6;10(5):2359-76. doi: 10.1021/pr101148r. Epub 2011 Mar 28.

15.

Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer.

Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC, Tibshirani R, Davis RW.

Clin Chem. 2008 Mar;54(3):582-9. doi: 10.1373/clinchem.2007.093195. Epub 2008 Jan 2.

16.

Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.

Fong ZV, Winter JM.

Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea. Review.

PMID:
23187839
17.

[Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].

Yang YC, Zhao YP, Liao Q, Zhang TP, Hu Y, Dai MH.

Zhonghua Wai Ke Za Zhi. 2009 Jul 1;47(13):999-1001. Chinese.

PMID:
19957811
18.

Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L.

Dig Dis Sci. 2004 Aug;49(7-8):1149-55.

PMID:
15387337
19.

Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.

Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.

Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.

20.

Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.

Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, Anderson MA, Shedden KA, Ruffin MT, Lubman DM.

J Proteome Res. 2014 Apr 4;13(4):1873-84. doi: 10.1021/pr400967x. Epub 2014 Mar 10.

Items per page

Supplemental Content

Write to the Help Desk